ACECAINIDE HYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H23N3O2.ClH
Molecular Weight	313.823
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1

InChI

InChIKey=IYEWBJUCJHKLHD-UHFFFAOYSA-N

InChI=1S/C15H23N3O2.ClH/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19;/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19);1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C15H23N3O2
Molecular Weight	277.362
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1693889 | https://www.ncbi.nlm.nih.gov/pubmed/9730262 | https://www.ncbi.nlm.nih.gov/pubmed/6188570 | https://adisinsight.springer.com/drugs/800000315 | https://www.ncbi.nlm.nih.gov/pubmed/11245854

Acecainide (N-acetylprocainamide), the N-acetylated metabolite of procainamide, is a Class III antiarrhythmic agent. Acecainide exerts cardiac anticholinergic effect. It elicits smooth muscle relaxation mainly through the activation of plasma membrane K+ channels. Acecainide markedly reduced premature ventricular beats and prevented induction of ventricular tachycardia. Acecainide appears to offer advantages over procainamide, particularly with respect to the reduced formation of antinuclear antibodies. Acecainide development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium channel 4 Target ID: Potassium channel Sources: https://adisinsight.springer.com/drugs/800000315 \| https://www.ncbi.nlm.nih.gov/pubmed/11245854	Antagonist 2778

PubMed

Title	Date	PubMed
Torsades de pointes due to n-acetylprocainamide.	1985 Jul	2410877
Study of procainamide hapten-specific antibodies in rabbits and humans.	1993 Nov	8253539
N-substituted benzamides inhibit nuclear factor-kappaB and nuclear factor of activated T cells activity while inducing activator protein 1 activity in T lymphocytes.	2001 Aug	11566320
Class I antiarrhythmics inhibit Na+ absorption and Cl- secretion in rabbit descending colon epithelium.	2005 Jun	16012869
St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays.	2006	16538644
Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment.	2006 Dec	17125432
Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma.	2006 Jan	16221756
Effect of drugs on defibrillation capacity.	2008	18370441
Drug therapy considerations in arrhythmias in children.	2008 Aug 1	18679519
Overview of therapeutic drug monitoring.	2009 Mar	19270474

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:26:42 GMT 2023` Edited by `admin` on `Fri Dec 15 15:26:42 GMT 2023`
Record UNII	B9K738KX14
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACECAINIDE HYDROCHLORIDE

Official Name

English

ASL-601

Code

English

BENZAMIDE, 4-(ACETYLAMINO)-N-(2-(DIETHYLAMINO)ETHYL)-, MONOHYDROCHLORIDE

Common Name

English

ACECAINIDE HYDROCHLORIDE [MI]

Common Name

English

4'-((2-(DIETHYLAMINO)ETHYL)CARBAMOYL)ACETANILIDE MONOHYDROCHLORIDE

Systematic Name

English

ASL 601

Code

English

ACECAINIDE HYDROCHLORIDE [MART.]

Common Name

English

ACECAINIDE HCL

Common Name

English

ACECAINIDE HYDROCHLORIDE [USAN]

Common Name

English

NSC-759312

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C47793